Group 1 - The article discusses the combination of avutometinib and defactinib for the treatment of recurrent low-grade serous ovarian cancer (LGSOC) and its commercial potential [2] - The author has a long position in Verastem, Inc. (NASDAQ: VSTM), indicating a positive outlook on the company's stock [3] - The article emphasizes the importance of innovative companies developing breakthrough therapies and pharmaceuticals with potential acquisition catalysts [2] Group 2 - The author has been involved in the healthcare investment sector for several years, focusing on biotech and life-saving therapies [2] - The article does not provide specific financial data or performance metrics related to Verastem, Inc. or the discussed drug combination [2]